

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

DR MOUHAMED YAZAN ABOU-ISMAIL (Orcid ID : 0000-0002-6682-4366)

DR MING YEONG LIM (Orcid ID : 0000-0001-5208-3387)

Article type : Research Article

## **Application of Radiochromic Gel Dosimetry to Commissioning of a Megavoltage Research Linear Accelerator for Small-Field Animal Irradiation Studies**

**Running Title: Gel dosimetry for small animal radiation**

*Noora Ba Sunbul\**

Department of Nuclear Engineering and Radiological Sciences, University of Michigan, Ann Arbor, MI, USA.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

*Ibrahim Oraiqt*

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA

*Benjamin Rosen*

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

*Cameron Miller*

Department of Nuclear Engineering and Radiological Sciences, University of Michigan, Ann Arbor, MI, USA.

*Christopher Meert*

Department of Nuclear Engineering and Radiological Sciences, University of Michigan, Ann Arbor, MI, USA.

*Martha M. Matuszak*

Department of Nuclear Engineering and Radiological Sciences, University of Michigan, Ann Arbor, MI, USA.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

*Shaun Clarke*

Department of Nuclear Engineering and Radiological Sciences, University of Michigan, Ann Arbor, MI, USA.

*Sara Pozzi*

Department of Nuclear Engineering and Radiological Sciences, University of Michigan, Ann Arbor, MI, USA.

**This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/MP.14685](https://doi.org/10.1002/MP.14685)**

This article is protected by copyright. All rights reserved

31 *Jean M. Moran*

32 Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

33 *Issam El Naqa*

34 Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

35 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA

36 \* *Corresponding author: nooraba@umich.edu, 2355 Bonisteel Blvd, Ann Arbor, MI 48109*

37

38 **Purpose:** To develop and implement an efficient and accurate commissioning procedure for small field static beam animal  
39 irradiation studies on an MV research linear accelerator (Linatron-M9) using radiochromic gel dosimetry.

40 **Materials:** The research linear accelerator (Linatron-M9) is a 9 MV linac with a static fixed collimator opening of 5.08 cm  
41 diameter. Lead collimators were manually placed to create smaller fields of 2x2 cm<sup>2</sup>, 1x1 cm<sup>2</sup> and 0.5x0.5 cm<sup>2</sup>. Relative  
42 dosimetry measurements were performed, including profiles, percent depth dose (PDD) curves, beam divergence, and relative  
43 output factors using various dosimetry tools, including a small volume ionization chamber (A14), GAFCHROMIC™ EBT3 film,  
44 and Clearview gel dosimeters. The gel dosimeter was used to provide a 3D volumetric reference of the irradiated fields. The  
45 Linatron profiles and relative output factors were extracted at a reference depth of 2 cm with the output factor measured relative  
46 to the 2x2 cm<sup>2</sup> reference field. Absolute dosimetry was performed using A-14 ionization chamber measurements, which were  
47 verified using a national standards laboratory remote dosimetry service.

48 **Results:** Absolute dosimetry measurements were confirmed within 1.4% ( $k = 2$ , 95% confidence = 5%). The relative output  
49 factor of the small fields measured with films and gels agreed with a maximum relative percent error difference between the two  
50 methods of 1.1 % for the 1x1 cm<sup>2</sup> field and 4.3 % for the 0.5x0.5 cm<sup>2</sup> field. These relative errors were primarily due to the  
51 variability in the collimator positioning. The measured beam profiles demonstrated excellent agreement for beam size (measured  
52 as FWHM), within approximately 0.8 mm (or less). Film measurements were more accurate in the penumbra region due to the  
53 film's finer resolution compared with the gel dosimeter. Following the van Dyk criteria, the PDD values of the film and gel  
54 measurements agree within 11% in the buildup region starting from 0.5 cm depth and within 2.6 % beyond maximum dose and  
55 into the fall-off region for depths up to 5 cm. The 2D beam profile isodose lines agree within 0.5 mm in all regions for the 0.5x0.5  
56 cm<sup>2</sup> and the 1x1 cm<sup>2</sup> fields and within 1 mm for the larger field of 2x2 cm<sup>2</sup>. The 2D PDD curves agree within approximately 2%  
57 of the maximum in the typical therapy region (1–4 cm) for the 1x1 cm<sup>2</sup> and 2x2 cm<sup>2</sup> and within 5% for the 0.5x0.5 cm<sup>2</sup> field.

58 **Conclusion:** This work provides a commissioning process to measure the beam characteristics of a fixed beam MV accelerator  
59 with detailed dosimetric evaluation for its implementation in megavoltage small animal irradiation studies. Radiochromic gel  
60 dosimeters are efficient small field relative dosimetry tools providing 3D dose measurements allowing for full representation of  
61 dose, dosimeter misalignment corrections and high reproducibility with low inter-dosimeter variability. Overall, radiochromic  
62 gels are valuable for fast, full relative dosimetry commissioning in comparison to films for application in high energy small-field  
63 animal irradiation studies.

64

65 **Index Terms;** Commissioning, Gel dosimetry, Animal irradiator and small field dosimetry.

66

## 67 **Introduction**

68 The planning and delivery of radiotherapy have been steadily becoming more complicated with sophisticated tools for daily  
69 image-guidance. These advances have rendered simple X-ray irradiators based on kilovoltage and orthovoltage X-ray machines  
70 incompatible with modern linear accelerator treatment delivery complexity. Hence, there is a burgeoning interest in developing  
71 small animal irradiators to scale down this complex system for radiobiological research [1]. These research irradiator devices use  
72 ionizing radiation as either X-rays or gamma rays for animal irradiation studies. Kilovoltage irradiators operate in the beam  
73 energy range of 10-120 kV, while orthovoltage units operate from 130-320 kV. These low energy irradiators can be used for  
74 either whole body, partial body or organ specific irradiations with a penetration depth from 0-2 cm [2]. Due to the limited energy  
75 range of animal irradiators, applications are restricted to small animals and superficial irradiations. However, high energy electron  
76 and photon irradiations for animal studies are possible with linear accelerators designed for clinical studies, i.e., the multi-  
77 modalities animal RT system (MultiART). MultiART is constructed by adopting existing commercial modalities such as Varian  
78 Clinac linac or SkyScan micro-CT to produce three different modes including kV and MV photon modes and MeV electron mode  
79 [3]. Image guided animal irradiators have been developed for higher accuracy in replicating clinical image guided radiation  
80 therapy with dose characteristics similar to the kV and orthovoltage irradiators [4].

81

82 Two common animal irradiator systems have been made commercially available: the Small Animal Radiotherapy Research  
83 Platform (SARRP) from Xstrahl Life Sciences developed at Johns Hopkins University, and the X-Rad SmART from Precision X-  
84 ray Inc developed at Princess Margaret Hospital, [5] [6][7][8]. While these commercially available image guided irradiators are in  
85 the kilovoltage range, the megavoltage irradiators are generally custom-developed from clinical linear accelerators. In this work,  
86 we discuss the commissioning process for repurposing a 9MV research linear accelerator as a small animal irradiator, capturing  
87 the megavoltage range of interest for relevant research purposes. While kilovoltage irradiators can mimic the clinical geometric  
88 setting, they lack effectiveness when considering preclinical radiobiological studies. Hence, the Linatron with its MV energy  
89 capabilities is more applicable for dosimetric and radiobiological studies mimicking the clinical dose responses especially for  
90 deep dose measurements with the MV energy beam.

91

92 Machine commissioning and quality assurance (QA) measurements of linear accelerators (linacs) are key components for  
93 accurate radiation therapy treatments. With advanced treatment planning and delivery techniques, comprehensive QA and  
94 commissioning are typically performed with a range of dosimeters to sample 3D volumes. Commonly used dosimetry tools such  
95 as ionization chambers, diodes, and Gafchromic films, could provide either point measurement or 2D dose distributions. With the  
96 increasing use of complex treatment plans and delivery techniques, more precise treatment planning verification dosimetry tools  
97 are needed. Gel dosimeters have gained recent interest in research due to their ability to precisely measure dose in 3D with  
98 relatively high resolution (sub mm spatial resolution) [9].

99

100 Several recommendations and guidelines were published to develop quality assurance procedures and to verify the dose delivery  
101 of clinical linear accelerators [10]–[12]. It is strongly recommended that protocols and guidelines similar to those used in  
102 commissioning animal irradiators and preclinical radiation research platforms be developed to maximize their impact in  
103 translating radiotherapy related research into the clinic [13],[14]. The aim of the comprehensive commissioning process is to fully  
104 characterize the dosimetric characteristics of the accelerators to reach a level of accuracy that is close to that employed for clinical  
105 radiation therapy irradiation (to deliver point dose values within 5% error [15]).

106  
107 As a result, there are various publications describing the commissioning and dosimetric beam characterization of commercially  
108 available small animal irradiator systems [16],[17],[18],[19][20]–[23]. Because commercially available animal irradiators are kV  
109 X-ray beam based accelerators, the commissioning process is recommended to follow the American Association of Physicists in  
110 Medicine Task Group #61 (TG61) report [14]. The Commissioning procedure of those commercial systems consists of output  
111 measurements and absolute dosimetry. The output factors have been measured in the literature using a suitable ionization  
112 chamber, radiochromic films, EDGE detector (diode) and gels [16],[17],[19],[24]. However, a previous study [17] has shown that  
113 conventional dosimeters like ion-chambers and diodes are not practically accurate due to volume averaging effects in small fields  
114 and demonstrated close agreement between EBT2 film and PRESAGE dosimetry for relative dosimetry measurements for fields  
115 larger than 10 mm in size. On the other hand, absolute dosimetry measurements have been performed in the literature using  
116 calibrated ionization chambers [16],[17],[19], and alanine [25].

117  
118 One of the main challenges in the commissioning process is the lack of independent dose verification process to assess the  
119 accuracy of dose delivery of the animal research irradiators. It has been recommended to follow a well-designed dose verification  
120 procedure for absolute dose verification to decrease uncertainties and to monitor dose delivery [25].

121  
122 With the increase in treatment planning and dose delivery complexity, there is an increased need for quality assurance for the  
123 treatment unit and patient specific dose delivery validation. 3D gel dosimetry is a promising dosimetry tool to verify advanced  
124 treatment delivery such as Intensity Modulated (IMRT), and Volumetric Arc Radiation Therapy (VMAT). One of the main  
125 applications of gel dosimeters is in basic dosimetry measurements because it has the capability to measure the dose distribution  
126 throughout a three-dimensional volume. Hence, it has advantages over many conventional dosimeters applied in basic electron  
127 and photon dosimetry parameter measurements such as beam profiles and percent depth doses [26]–[29].

128  
129 In order for a 3D dosimetry tool to be clinically useful, the Resolution-Time-Accuracy-Precision (RTAP) performance criteria  
130 proposed by Mark Oldham *et al.* should be fulfilled. An ideal 3D dosimetry system, including the dosimeter and associated  
131 readout, is defined under RTAP to be able to deliver 3D dose measurements with 1 mm isotropic spatial resolution in less than  
132 one hour with an accuracy of 3% and a precision of 1%.[30]

133  
134 Gels are chemical dosimetry systems that are imaged with readout systems to quantify their response to radiation. There are  
135 several 3D dosimeters such as normoxic polymer gels, radiochromic plastics (i.e., PRESAGE) and radiochromic gel dosimeters.  
136 The main imaging modalities used for 3D dose readout are MRI[35], optical CT (optCT) and X-ray computed tomography (CT)

[9], [13], [31][32][33]. Optical CTs are analogous to the common X-ray CT in their scanning principle except that they use a visible light source. The motivation for developing the X-ray (CT) and optCT readout systems was the desire to make 3D imaging readout more readily available and easily accessible [38], [39] [9][34].

The dose quantifications for 3D dosimetry systems using MRI results is based on the dependence between the dose and the nuclear magnetic relaxation (NMR) properties of the dosimeter under irradiation [9], [13], [40]. While the dose quantification in optCT based dosimeters is based on the radiation induced changes in the transparency of the color of the dosimeter material at visual wavelengths which enables optCT imaging and hence dose quantification[36]. For radiochromic dosimeters, the optical response is a primary result of absorption based light attenuation, which has the advantage of minimal scattered light perturbation.

Previous studies have shown that certain polymer gel dosimeters are dose rate dependent, which could result from competing radiation-induced chemical reactions. This effect has been more pronounced in a normoxic THP-based methacrylic acid (MAc) gel dosimeters than in poly-acrylamide-gel (PAG) dosimeters [42]–[45]. The commonly used radiochromic polymer gel PRESAGE™ is designed for use with optical CT. It has the advantages of high resolution, relatively low noise, and linear optical response to radiation dose to within 1%. However, it has little dependency on dose rate (~2%) [29], [46].

Clearview gels (Modus Medical, London, Ontario) are radiochromic 3-D dosimeters designed by Modus Medical Devices Inc to be read by Optical-CT (Modus Medical, London, Ontario) [47]. After gels have been exposed to ionizing radiation, their clear color changes to pink/purple due to the formation of a formazan dye within the gel [48]. The measurement dose range is 10–80 Gy, and gels have been shown to have a linear dose response up to 80 Gy, and to be independent of photon beam energy (4–18 MV) and dose rate (up to 9.9 Gy/min) [48]. The post-irradiation dose stability has been studied and shown to be consistent for at least one week post-irradiation with uniform inter-batch stability[49]. Based on these characteristics, gels provide benefits for relative dosimetry; however, gels have been shown to have a limited detectability of the surface and near surface doses up to 4-5 mm depths due to the reconstruction artifacts [17],[49].

Small radiation fields are defined as those fields that may lack charged particle equilibrium due to their smaller field size relative to the lateral range of the charged particles [12]. Because the commonly used dosimeters are considered large with respect to the small fields, this study aims to verify the 3D relative dosimetry applicability of Clearview gel dosimeters for small radiation field measurements. The verification is performed through the detailed characterization and commissioning of a 9 MV research Linatron as a small field animal irradiator intended to capture MV physical and biological interactions. Radiochromic Clearview gels have the advantage of independent dose rate response over the more commonly used polymer gels. In this work, the feasibility of Clearview gels as a relative 3D dosimetry tool is tested for accuracy and efficiency by capturing the percent depth dose curves, beam profiles and relative output factors (ROFs) of different small fields in comparison to EBT3 Gafchromic films [50].

## Materials and methods

### *The research small field linear accelerator*

The research linear accelerator (Linatron-M9) is a 9 MV flattening-filter-free photon-mode accelerator that has a fixed target and a single electron energy mode (9 MeV), which produces a “9 MV” bremsstrahlung photon beam [51]. The Linatron has a static beam with a horizontal collimator opening of 5.08 cm in diameter to shape a static circular beam size, FWHM, of approximately 7.5 cm in diameter at the calibration point of 220 cm from the source target. This Linatron was originally installed for active interrogation nuclear material detection research. Hence, for the repurposing of the Linatron as a small animal irradiator, lead collimation bricks were manually placed at the exit of the beam as a secondary collimator to shape the beam to smaller fields of  $2 \times 2 \text{ cm}^2$ ,  $1 \times 1 \text{ cm}^2$  and  $0.5 \times 0.5 \text{ cm}^2$  horizontal beams (Fig. 1) at the calibration point of 220 cm source to surface distance (SSD). This manual collimation of the beam allows for a simple repurposing of the Linatron to widen its research applicability as an MV small field animal irradiator. Positioning lasers were manually integrated to the Linatron to increase collimator and phantom positioning reproducibility and reduce alignment errors (Fig. 1 a, b).

As previously mentioned, the effective point of calibration and measurement SSD was located at 220 cm. Measurement points were selected to balance the SSD (for machine output) and adequate distance for the measurement setup. The Linatron output (LO) is controlled either in the unit of irradiation time (seconds) or as the total dose (Gy) by the built-in ionization chamber monitor placed at 100 cm from the source.

#### ***Absolute dosimetry measurement***

Absolute measurement of the Linatron output was performed using a  $15 \text{ mm}^3$  effective volume thimble ionization chamber (A14) [52]. The output measurements were performed for the machine specific static collimated field of the Linatron, 7.5 cm in diameter beam size at 220 cm SSD. All correction coefficients including recombination, polarity, pressure and temperature were applied following the AAPM TG-51 calibration protocol [11]. However, due to the geometrical constraints of this system, it is impractical to reach the reference condition of 100 cm SSD, as reported in the TG51 recommendations. Some modifications had been made to the AAPM TG51 protocol, due to the difference in dimensions and accessibility of the Linatron machine compared to a clinical machine. The ionization chamber was cross-calibrated using a clinical Varian TrueBeam linac (Varian Medical Systems, Palo Alto, Ca) to ensure higher accuracy of our dose calibration method. The beam quality of the Linatron was simulated using EGSnrc (BEAMnrc/DOSXYZnrc) Monte Carlo codes in a water phantom and verified in a solid water measurement using the tissue phantom ratio (TPR) at depths of 20 and 10 cm (TPR20/10) for a field of 11.28 cm diameter (10cm x 10cm square equivalent field)[10], [53], [54]. The relative percentage error between the two methods was  $\sim 0.16\%$ .

The absolute Linatron output stability was measured during its daily operations (at different operation hours) on two different weeks within a month-long period. The variation of the daily first Linatron operation output was measured for each weekly experimental operation of the Linatron during that measurement month. The time linearity of the Linatron output (in minutes) was measured and verified with the A14 ionization chamber dose measurement in Gy (Fig. 1:a).

#### ***Clearview gel measurement***

3D dosimetry measurements including PDD curves, beam profiles and output factors of the small fields were performed using different Clearview gel dosimeter jars (Modus Medical Devices Inc.) [47]. The gel jars were from two different batches; therefore, each batch was calibrated separately. Each field was measured three times using the same dosimeter jar while allowing

210 enough separation between the fields in order to not affect the measured dose distributions [17], [31]. All experiments were  
211 acquired at the same SSD, 220 cm from the Linatron target, at a relative inter-gel depth of 2 cm (Fig. 1:b). SSD and depth of  
212 measurements were selected because the reference conditions specified in the standard dosimetry protocols [11] for beam  
213 calibrations cannot be met for this accelerator.

214 Dose profiles were extracted at a depth of 2 cm for all fields. Gel dosimeters were scanned with a Vista optical CT scanner  
215 Model: 16 (Modus Medical, London, Ontario). The resolution was set to 0.5 mm for all scanned gels using the iterative back  
216 projection image reconstruction technique for better scanning and image resolution than the simple back projection reconstruction  
217 [56]. The jars were marked for accurate repositioning of the dosimeter in reference to the background correction scan. All the gels  
218 were scanned pre-irradiation exposure to compensate and correct for the background reading following manufacturer  
219 recommendations. All jars including the calibration and measurements were scanned within 24 hours of exposure to ensure signal  
220 stability. Each batch of gels was calibrated using a 9 MeV electron beam to provide absolute dosimetry readings.

221 The gel calibration was performed using a clinical Varian TrueBeam linac (Varian Medical Systems, Palo Alto, Ca) to ensure  
222 higher accuracy of the dose calibration. A 9 MeV electron beam using the standard 10 cm x 10 cm cutout, with SSD=100 cm, and  
223 30 Gy delivered to  $d_{max}$  (2.0 cm) was used. The gel central-axis attenuation coefficient change (i.e., optical density change) was  
224 measured using the Vista Optical-CT and fitted linearly with the corresponding central-axis depth dose. The 9 MeV electron  
225 beam calibration is recommended by the gel manufacturer so that a full depth dose curve (100% to <5%) can be measured using a  
226 single gel phantom. The electron beam is a simple way of compressing a wide dynamic dose range into the space of the jar [57].  
227 The calibration curves were then obtained using a linear fit to relate the optical density to dose in Gy as shown in Fig. 2:a. This  
228 calibration procedure is sufficient only for relative dose measurements and is insufficient for absolute dosimetry due to potential  
229 energy dependence concerns. Gel analysis was performed using in-house developed MATLAB codes that have been validated  
230 using spot checks and redundancy algorithms. The common procedure that was adopted for the gel measurement is [49]:

- 231 – gels were stored at  $\sim 4$  °C temperature (in a refrigerator)
- 232 – gels were returned to room temperature prior to irradiation (approximately 8 hours before irradiation gels were removed from  
233 refrigerator)
- 234 – gels were read at room temperature,
- 235 – gels were sheltered from light as much as possible during transport, setup, and handling using light-tight opaque bags.

236

### 237 **Film measurement**

238 EBT3 Gafchromic films (Ashland, Bridgewater, NJ) [50] were used in the same measurement setup as the gels for 2D relative  
239 dosimetry measurements of PDDs, ROFs, beam profiles and beam divergence. Solid water (Gammex Solid water) slabs of 2 cm  
240 thickness were used for dose buildup (Fig. 1:c).

241 Films were scanned with EPSON scanner Model: EU-88 set to the professional mode. The resolution was set to 150 dpi for all  
242 scanned films. All calibration and measurement films were scanned at least 24 hours after the film exposure to ensure adequate  
243 film saturation before scanning [58]. The scanned films were analyzed using FilmQA Pro (Ashland Scientific software [59]) and

MATLAB codes following the AAPM (TG-47) specifications [60]. All the films were exposed for at least 2 minutes to decrease the effect of noise and, therefore, the associated errors that are expected at the small optical density values [58].

The film calibration curve was established for doses ranging from 0 (un-irradiated film) up to 8 Gy (Fig. 2:b). The un-irradiated film was used to determine the necessary background correction, while the 8 Gy film represents the maximum expected measured dose. The radiochromic films were calibrated using the three-color components: red, green and blue. However, the analysis was performed using the red color component since it has higher sensitivity [61].

All measurements were reported as the average of three different trials to inherently assess the overall reproducibility of the measurement using gels and films. The accuracy of the secondary collimator setup (the manual collimator positioning misalignment) was measured by evaluating the variability among six different trials (3 different setups per person). The collimator positioning uncertainty is estimated as the standard deviation of the measured output ( $D_{\max}$ ) of the field, with  $D_{\max}$  referring to the maximum dose at the central  $2 \times 2 \text{ mm}^2$  ROI of both the  $0.5 \times 0.5 \text{ cm}^2$  and the  $2 \times 2 \text{ cm}^2$  fields.

### ***Commissioning applicability in animal irradiations***

After the full commissioning, the Linatron was applicable as an animal irradiator for rabbit irradiation and dose measurements (Fig. 3). The Linatron output measured with A-14 IC in Gy was calculated to estimate and control the intended dose at the point of irradiation for animal irradiation studies. The relative output factor of the  $2 \times 2 \text{ cm}^2$  field of interest in the animal irradiation work was measured relative to the open Linatron field with A-14 IC and verified with the film measurements. Hence, the measurement dose at the point of irradiation for all fields can be calculated using the MU formula recommended by TG-71 [62]. The absolute dosimetry accuracy was verified in-house with an A-14 ionization chamber and then independently with a TLD using a remote dosimetry service. The remote dosimetry service included TLD calibration, analysis and readouts and was performed at the University of Wisconsin-Madison Radiation Calibration Laboratory for more accurate measurement of the output reproducibility and calibration effectiveness.

**Fig. 1.** Relative and absolute dosimetry measurement setup at 220 cm SSD and effective measurement depth of 2 cm in phantom (2 cm buildup thickness of solid water (a,e) or gel (b) ) (a) measurements setup using A14 ionization chamber (b) radiochromic gel jar (c) film measurement. Fig. 1 b) shows the integrated positioning lasers used to increase collimator and phantom positioning reproducibility and reduce production errors.

**Fig. 2.** (a) Clearview gel calibration curve relating optical density to dose in Gy and (b) the three color (red, blue, green) components of the film calibration curve relating the percent color response of the film to dose in Gy.

**Fig. 3.** Example rabbit irradiation setup showing the utilization of commissioned Linatron in small animal irradiation studies. (a) An euthanized rabbit was supported vertically with build-in holder and exposed to a  $2 \times 2 \text{ cm}^2$  field at 220 cm SSD (b). The total maximum dose was maintained to be  $< 20 \text{ Gy}$  per fraction as per the institutional animal protocol [63].



278

279 **Results**280 *Linatron output constancy and time linearity*

281 The Linatron output is controlled either per time unit or as total dose (cGy). IC measurements were performed to verify the  
 282 Linatron output (cGy/min) variability with time and by measuring the timer-to-output Linatron linearity. The Linatron output  
 283 variability with time after the first irradiation was measured on two different days within a month period with a standard deviation  
 284 between the absolute dose readings of 0.61% and 0.48% on the first and second day. The Linatron output increases with time  
 285 after its first operation. The variability of the Linatron output at its first operation was 0.51% corresponding to absolute dose  
 286 variability measured with A-14 IC weekly of 0.55% on four different days over nearly a month. Overall, the reported variability  
 287 of the Linatron during its expected operational hours is <1% (Table 1,

288 Table 2) as verified with the measured dose of A-14 IC. The total dose measured at variable irradiation times (minutes) was  
 289 found to follow a linear trend as expected with a reported  $R^2$  value of 1 based on the A14 IC dose readings in cGy and the  
 290 Linatron output reading as well (Fig. 4). The Linatron output rate (cGy/min) remained relatively constant during the total  
 291 irradiation time with an average of  $600.44 \pm 0.76$  cGy/min which was verified with the A-14 IC to be  $145.60 \pm 0.29$  cGy/min.

292

293 **Table 1.** Daily Linatron output variability with time (intra-day variability) for 3 minutes of irradiation

294

295 **Table 2.** First operation Linatron output variability with date of exposure (inter-day variability).

296

297 **Fig. 4.** Linatron output-timer linearity absolute measurement verification with A14 IC; absolute total dose measured as the average of three  
 298 different trials and the error is the standard deviation between trials. The smaller error bars (much smaller than the marker sizes) represent the  
 299 uncertainty in the measurements.

300

301 *Small field relative dosimetry*

302 The full 3D dose distributions were measured with gels (Fig. 5) and used to extract beam characteristics and relative dosimetry  
 303 including beam profiles, PDDs and ROFs. The relative dose gel results were then compared with the 2D dose distributions  
 304 extracted at the corresponding orientation using films.

305

306 **Fig. 5.** 3D view of gel dose measurements (in optical density OD) per pixel position for the  $1 \times 1$  cm<sup>2</sup> field showing the transverse and sagittal  
 307 views of dose distributions in b, c for extracting beam profiles at 2 cm depth, and PDD curves respectively.

### 308 *Beam profiles*

309 The average beam profiles, expressed as full width at half maximum (FWHM), were measured with gels and films (Fig. 6 for  
 310 horizontal and vertical beam profiles). The main characteristics of each small field, such as FWHM and (20–80%) penumbras,  
 311 were listed in Table 3. The overall average collimation positioning uncertainty was measured to be 1.93% and 4.18% for the 2x2  
 312 cm<sup>2</sup> and the 0.5x0.5 cm<sup>2</sup> field, respectively.

314 **Fig. 6.** Beam profiles of the 0.5x0.5 cm<sup>2</sup>, 1x1cm<sup>2</sup> and 2x2 cm<sup>2</sup> fields measured with gel dosimeter and EBT3 films at 2 cm reference depth in  
 315 phantom; (a) the horizontal (in plane) beam profiles, (b) is the vertical (cross plane) beam profiles. Due to limited sensitivity of the gels for low  
 316 doses, gel profiles were limited to absolute doses above 8 Gy.

318 **Table 3.** Beam profile characteristics at 2 cm depth in phantom using films and gels

319 \* A minimum error value in measurement of 0.01 cm is reported here for the beam profiles extracted from film. Similarly, for the error value in  
 320 the right penumbra measured with both gel and films.

### 322 *Percent Dose Depth Curves*

323 Fig. 7 shows the measured percent depth dose (PDD) curves for the three small fields. Data were measured with both EBT3  
 324 Gafchromic films and gel dosimeters. Each curve is represented as the average of three different measurement trials. The error  
 325 bars are reported as the standard deviation between the individual readings. Both film and gel curves were normalized to the  
 326 average maximum measured dose. The PDD values from the film and gel measurements agree within 11% in the buildup region  
 327 starting from 0.5 cm depth and within 2.6 % at tail region depths up to 5 cm.

329 **Fig. 7.** PDD curves, an average of three different trials, for each of the small radiation fields (a) Film based PDDs for all fields (b) 0.5x0.5 cm<sup>2</sup>,  
 330 (c) 1x1 cm<sup>2</sup>, (d) 2x2 cm<sup>2</sup> measured with gels and films. Error bars are represented for both film and gel as the point standard deviation between  
 331 the three different trials.

### 333 *Relative Output Factors*

334 The output factors for the small fields were measured relative to the 2x2 cm<sup>2</sup> collimated field and reported in

335 Table 4. Film and gel output factor measurements were calculated at the reference depth of 2 cm in a region of interest of 2x2  
 336 mm<sup>2</sup> for the three field sizes measured. The reference depth of 2 cm was selected to simplify the Linatron output dose  
 337 calculations for animal irradiations as it is the estimated skin to liver distance for rabbit measurement applications. The relative  
 338 percent difference between gel and film measurements was 1.1 % for the 1x1 cm<sup>2</sup> field and 4.3 % for the 0.5x0.5 cm<sup>2</sup> field. The

339 major contribution to this error was the manual positioning of the collimator, as both measurements were performed on different  
 340 days and with independent manual collimation setups.

341 The output factor for the 2x2 cm<sup>2</sup> field and the 0.5x0.5 cm<sup>2</sup> was reported as three different trials per person to decrease the effect  
 342 of the collimation positioning in the overall measurement and ensure compatibility with the gel results, which were performed at  
 343 a different collimation setting.

344

345 **Table 4.** ROFs of the different Linatron field sizes relative to the 2x2 cm<sup>2</sup> field

346

347 ***Beam Divergence and inverse square law***

348 Measurements were performed for the open 5.08 cm diameter field size using EBT3 Gafchromic films at different SSDs to  
 349 measure the divergence of the beam (Fig. 8). The beam field size diverges linearly with SSD. The measured beam size, FWHM,  
 350 values agree with the mathematically expected beam divergence values within ~1.8% difference except at the beam exit point due  
 351 to the collimation positioning uncertainty in beam exit collimation (Table 5).

352 Fitting the absolute dose values measured with film to the SSD distances results in an inverse square fitting with an R<sup>2</sup> of nearly  
 353 unity (0.999), as expected due to the inverse-square law (Fig. 9). Variations in solid water positioning used for 2-cm buildup led  
 354 to some profile asymmetry, which affected the scatter for film divergence measurements and hence beam symmetry (Fig. 8).

355

356 **Fig. 8.** Beam profiles of primary collimated Linatron beam divergence (5.08 cm diameter) with distance from the beam exit measured with  
 357 films at beam exit, 1.25 m and at 2.5 m from beam exit.

358

359 **Table 5.** The field size diversion data with distance from the target source

360

361 **Fig. 9.** Inverse-square law fitting verification of dose (in Gy) measured with films as a function of distance from source (in meters).

362

363 ***2D Contour plots of Clearview gel compared with film***

364 ***Beam profile:***

365

366 The profile contour plots were extracted at a depth of 2 cm for all field sizes using both the EBT3 and Clearview gels, as shown  
 367 in Fig. 10. The isodose lines agree within 0.5 mm for all fields up to 1 x 1 cm<sup>2</sup> and within 1 mm for the 2x2 cm<sup>2</sup> field. Overall,

these isodose lines show excellent agreement for the three fields, taking into consideration the small dimension of the fields and the differences in the resolution of the imaging modalities used in this study.

**Fig. 10.** Isodose contour plots of the different small field profiles at a depth of 2 cm for gels and films. Isodose lines are 90, 80, 60, and 40%. a) 0.5x0.5 cm<sup>2</sup> field, b) 1x1 cm<sup>2</sup> field and c) 2x2 cm<sup>2</sup> field.

#### ***PDD curves:***

Fig. 11 compares the curves acquired from the film and the Clearview gels at the central beam region along the beam direction. All curves agree within approximately 2% of the maximum in the typical therapy region (1–4 cm). The EBT3 curves were slightly steeper (~ 12% at 2.5-4 cm) for the 0.5x0.5 cm<sup>2</sup> field. The main contribution of this difference is film misalignment, which causes the curve to fall off more steeply for films in comparison to gel. As measured in this study, there is an inherent approximated collimation placement error of 4.18% for the 0.5x0.5 cm<sup>2</sup> field, which also contributes to the discrepancy as both measurements were performed at different collimation setup. A correction factor relating the PDD measurement along the beam direction at 2 cm to the output dose measured across the beam direction at 2 cm depth was applied to correct for the film positioning relative to the beam center. This approach improved the agreement between the film and gel measured PDD curves to be within approximately 5% in the typical therapy region (1–4 cm) as shown in Fig. 11a.

Overall, film measured PDDs are steeper than those of the gel for all the fields. The main cause of this effect is not clearly known and as stated in literature the main causes are the expected reduction in the accuracy of film data at depths deeper than 2 cm. Additionally, the film misalignment would cause the curve to decrease more steeply. The relative differences in electron density of the EBT3 film and gels could contribute to this effect as well

**Fig. 11.** Isodose contour plots (90, 80, 70, 60,50 and 40%) for the different small field plane PDDs for gels and films normalized to the maximum dose. A) 0.5x0.5 cm<sup>2</sup> field, b) 1x1 cm<sup>2</sup> field and c) 2x2 cm<sup>2</sup> field.

#### ***Commissioning applicability in animal irradiations***

The Linatron calibration factor was measured to be  $600.93 \pm 1.12$  cGy/min. While the output factor of the 2x2 cm<sup>2</sup> relative to the reference circular field of 5.08 cm diameter was measured with both A-14 IC and verified with films to equal  $0.94 \pm 0.002$  and  $0.94 \pm 0.02$ , respectively. The absolute dosimetry accuracy was verified through exposing two separate dosimeters (A-14 IC and TLD) to a total dose of 100 cGy. The average readings of both were  $101.37 \pm 0.52$ ,  $101.09 \pm 0.57$  cGy, respectively. The Linatron output is hence measured and verified with an error of <1.4%.

#### **Discussion**

401 The dose linearity with exposure time of the Linatron was tested for only the expected operational duration of the Linatron for  
402 animal studies (up to approximately 10 minutes). The overall output variability is always less than 1% after a few hours of non-  
403 continuous operation (Table 1,

404 Table 2). The lead collimator positioning uncertainty contributes to the higher uncertainty in the measurement reproducibility  
405 especially for the smaller field size of  $0.5 \times 0.5 \text{ cm}^2$ , which could be as high as 4.18%. This uncertainty was calculated ignoring the  
406 other relevant uncertainties such as film uncertainties and the Linatron output variability as each is considered to be less than 1%.  
407 To increase the reproducibility of the lead brick positioning, we recommend for future work that the output is measured after  
408 collimation positioning prior to any experiments to maintain a higher accuracy of the dose delivery and monitoring as applied in  
409 the  $2 \times 2 \text{ cm}^2$  output check for animal irradiation experiments. However, it is noticeable that with repeatability of the  
410 measurements, the overall positioning becomes more reproducible. This reproducibility is reflected with the relatively smaller  
411 relative percent difference between the gel and film measurements of the ROF that were performed on different days and with  
412 independent manual collimation setups.

413 The smaller collimated field ( $0.5 \times 0.5 \text{ cm}^2$ ) exhibits higher uncertainty in the collimation placement and, therefore, higher  
414 measured collimator positioning uncertainty in comparison to the  $2 \times 2 \text{ cm}^2$  field. On the other hand, the variability of the per-field  
415 output could be 1.1 % for the case of the  $1 \times 1 \text{ cm}^2$  field when the collimation was kept in position. These measurements show that  
416 the major expected source of measurement variability is due to the positioning uncertainty of the secondary collimators. The  
417 differences in the measured beam sizes by gels to those measured with films (Table 3) are a maximum of approximately 0.8 mm.  
418 The difference in the resolution of the two methods is the main cause of this discrepancy between the beam profile results. The  
419 measured ROFs for the  $1 \times 1 \text{ cm}^2$  and  $0.5 \times 0.5 \text{ cm}^2$  are within a maximum relative error of 0.8%, 12.6% from the MC simulated  
420 results. The higher error for the smaller field was mainly caused by the collimation positioning error, which was measured to be  
421 4.18%. A 1 mm spatial displacement of the collimation position of the  $0.5 \times 0.5$  field was simulated to cause a corresponding drop  
422 in the simulated ROF value by as high as 21%. Thus, that caused the measured ROF to be lower than the simulated value. In  
423 addition, Monte Carlo methods for very small fields are difficult due a range of factors, including the approximation of a point  
424 source which is unable to properly replicate potential source occlusion in dose measurements. Since our two measurement  
425 methods congruently indicate output factors lower than simulated, we believe the source occlusion could be an additional source  
426 of uncertainty.

427 Additionally, Fig. 6 shows limited out-of-beam dose measurement (profile edges) with Clearview gels in comparison to films due  
428 to the limited sensitivity of the gels for low doses; hence, gel profiles were limited to absolute doses above 8 Gy. This  
429 measurement was designed to exclude the effect of background measured OD differences and exclude stray light noise. The  
430 higher error bars between various measurement trials in the profile edges (penumbra region) was due to the effect of the coarser  
431 resolution of the gels in comparison to the films as shown in Fig. 6.

432 The gel measured PDDs show higher uncertainty in the buildup region up to 0.5 cm due to the effect of image reconstruction  
433 artifacts from stray light and light refraction at the surface of the gel. This uncertainty limits the use of gels for surface dose  
434 measurements [49][17]. The depth of the maximum dose, as well as the surface dose (as measured with films), increases with the  
435 field size due to the scattering within the phantom as shown in Fig. 7.a. The error between the three different trials of the film  
436 measurement is higher for the smaller field sizes due to the alignment difficulty of films at the central region of the smaller fields.

437 Although films can provide highly accurate relative profile dose distributions, they are difficult to place parallel to the beam  
438 direction due to the higher possibility of angular misalignment with depth. Gel dosimetry was more robust and efficient in  
439 capturing the 3D dose distributions. For gel-based percent depth dose measurements, dose readings were acquired along the  
440 central ROI by averaging  $2 \times 2 \text{ mm}^2$  on each slice centered in the dose center of the field. This approach was performed to correct  
441 for any angular misalignments of gel with depth. Hence, the Clearview gel PDD at deeper depths ( $>3 \text{ cm}$ ) is expected to be more  
442 accurate than film acquired PDDs especially for the smaller fields of  $0.5 \times 0.5 \text{ cm}^2$  and  $1 \times 1 \text{ cm}^2$ .

443 The depth of maximum dose was measured to be in a good agreement with the film results with a maximum of 1 mm difference.  
444 This difference is due to the uncertainty associated with the dosimeter surface artifacts that affected the accuracy of the  
445 determination of the startup slice. This uncertainty was corrected through maximum dose alignment for the PDDs to well predict  
446 the surface slice of the Clearview gel. This uncertainty could have been eliminated by marking the relative positioning of the  
447 reference depth at the edge of the gel dosimeter. The percent difference error between film and gel acquired PDDs was  $< 2\%$  for  
448 depths from 0.5 cm to 8 cm. The accurate dosimetry within this depth for the  $2 \times 2 \text{ cm}^2$  field is sufficient for small animal  
449 irradiations of interest.

450 Overall, the standard deviation between the different gel trials is much lower than the corresponding standard deviation between  
451 the film trials for measuring PDDs and ROFs. That reflects the higher intra-stability of the gel jars and hence their effectiveness  
452 for measurement reproducibility allowing multi-trials of small field characterization with the same gel jars. Gels, therefore, allow  
453 higher measurement accuracy and reproducibility.

454 The 2D isodose lines shows good agreement between EBT3 and the Clearview gels at a typical therapy depth of 2 cm. The  
455 isodose lines agree within 0.5 mm for the smaller fields and within 1 mm for the larger field of  $2 \times 2 \text{ cm}^2$ . This agreement was  
456 comparable to the reported values in literature comparing films to PRESAGE gel [17].

457 All of the 2D PDD isodose line curves agree within approximately 2% of the maximum in the typical therapy region (1–4 cm) for  
458 the field sizes of  $1 \times 1 \text{ cm}^2$  and  $2 \times 2 \text{ cm}^2$ . Film misalignment causes the curve to fall off more steeply for films in comparison to gel.  
459 This effect in addition to the collimation placement error of 4.18% has higher effect on the smaller field of the  $0.5 \times 0.5 \text{ cm}^2$ . A  
460 correction factor that relates the PDD measurement to the output dose measured across the beam direction at 2 cm depth  
461 improved the agreement between the film and gel measured PDD curves to be within  $\sim 5\%$  in the typical therapy region (1–4 cm).  
462 Overall, the gel measured PDD curves are expected to be more accurate than those measured with film especially at deeper depths  
463 ( $> 3 \text{ cm}$ ) as gels has measured the full 3D data allowing for any dosimeter misalignment correction.

464  
465 As a preliminary step for animal irradiations based on the full commissioning work, a verification measurement is recommended  
466 to check the  $2 \times 2 \text{ cm}^2$  field output value for the field pre-animal irradiation. This will allow for more accurate dose control through  
467 minimizing the secondary collimation dispositioning error.

468

469

470

471

472

473

**474 Conclusions**

475 This work provides a simple and accurate commissioning process to measure the beam characteristics of an MV research  
476 accelerator with detailed 3D and 2D dosimetric evaluation for its implementation as a megavoltage irradiator for radiobiological  
477 and dosimetric studies in small animals. The effectiveness of radiochromic gel dosimetry as a robust and efficient 3D dosimetry  
478 tool for small field studies is verified through the relatively acceptable agreement to film measurements. The relative dosimetry  
479 results including beam profiles, PDDs and ROFs of are in good agreement with film results for all three tested small fields. These  
480 results emphasize the effectiveness of ClearView gels as a relative dosimetry tool especially given their dose-rate and energy  
481 independent response. Although, the dosimetric response of the Clearview gels is limited in the buildup region due to artifacts  
482 near the surface, 3D gel dosimeters showed the advantage of minimizing the dosimeter misalignment uncertainties, which is the  
483 main challenge in small field measurements. Clearview Gels provided the full 3D dose measurement allowing for full  
484 representation of dose and dosimeter misalignment corrections. Although gels have limited accuracy in the surface and near  
485 surface regions, the high agreement between the different gel trials using the same gel dosimeter showed low inter-dosimeter  
486 variability. Hence, Clearview gels have the advantage of measuring multiple small fields and field parameters using the same  
487 single dosimeter.

488

489

490

491

492

493

494

495

**496 Acknowledgments**

497 This research was supported in part by National Institutes of Health (Grant R37CA222215). This work, and the linear accelerator  
498 loan, have been supported in-part by the US Department of Homeland Security, Countering Weapons of Mass Destruction  
499 Office, Academic Research Initiative under Grant No. 2016-DN-077-ARI106. It was partially funded by Hadramout  
500 Establishment for Human Development (HEHD) fellowship and University of Michigan MCubed research funding. Clearview

gels were provided by Modus Medical, London, Ontario. The authors would like to thank Cliff Hammer from the University of Wisconsin Medical Radiation Research Center for providing the independent TLD dose verification.

#### Conflict of interest

The authors have no conflicts to disclose.

#### References

- [1] F. Verhaegen, P. Granton, and E. Tryggestad, "Small animal radiotherapy research platforms," *Phys. Med. Biol.*, vol. 56, no. 12, 2011.
- [2] T. Yoshizumi, S. L. Brady, M. E. Robbins, and J. D. Bourland, "Specific issues in small animal dosimetry and irradiator calibration," *Int. J. Radiat. Biol.*, vol. 87, no. 10, pp. 1001–1010, 2011.
- [3] T. C. Chao, A. M. Chen, S. J. Tu, C. J. Tung, J. H. Hong, and C. C. Lee, "The evaluation of 6 and 18 MeV electron beams for small animal irradiation," *Phys. Med. Biol.*, vol. 54, no. 19, pp. 5847–5860, 2009.
- [4] S. Sharma *et al.*, "Advanced Small Animal Conformal Radiation Therapy Device," *Technol. Cancer Res. Treat.*, vol. 16, no. 1, pp. 45–56, 2017.
- [5] M. Ghita, K. H. Brown, O. J. Kelada, E. E. Graves, and K. T. Butterworth, "Integrating small animal irradiators with functional imaging for advanced preclinical radiotherapy research," *Cancers (Basel)*, vol. 11, no. 2, 2019.
- [6] J. C. Crosbie *et al.*, "Tumor Cell Response to Synchrotron Microbeam Radiation Therapy Differs Markedly From Cells in Normal Tissues," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 77, no. 3, pp. 886–894, 2010.
- [7] J. Wong *et al.*, "High-Resolution, Small Animal Radiation Research Platform With X-Ray Tomographic Guidance Capabilities," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 71, no. 5, pp. 1591–1599, 2008.
- [8] N. Cho *et al.*, "Validation of GPU-accelerated superposition–convolution dose computations for the Small Animal Radiation Research Platform," *Med. Phys.*, vol. 45, no. 5, pp. 2252–2265, 2018.
- [9] L. J. Schreiner and T. Olding, "Gel Dosimetry," in *#34 Clinical Dosimetry Measurements in Radiotherapy (2009 AAPM Summer School)*, 2009, p. 1112.
- [10] "Technical Reports Series No. 483: Dosimetry of Small Static Fields Used in External Beam Radiotherapy; An International Code of Practice for Reference and Relative Dose Determination," 2017.
- [11] P. R. Almond *et al.*, "AAPM's TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams," *Med. Phys.*, vol. 26, no. 9, pp. 1847–1870, 1999.
- [12] H. Palmans, P. Andreo, M. S. Huq, J. Seuntjens, K. E. Christaki, and A. Meghziene, "Dosimetry of small static fields



used in external photon beam radiotherapy: Summary of TRS-483, the IAEA–AAPM international Code of Practice for reference and relative dose determination,” *Med. Phys.*, vol. 45, no. 11, pp. e1123–e1145, 2018.

[13] F. Verhaegen *et al.*, “ESTRO ACROP: Technology for precision small animal radiotherapy research: Optimal use and challenges,” *Radiother. Oncol.*, vol. 126, no. 3, pp. 471–478, 2018.

[14] C. M. Ma *et al.*, “TG61:AAPM protocol for 40-300 kV x-ray beam dosimetry in radiotherapy and radiobiology,” *Med. Phys.*, vol. 28, no. 6, pp. 868–893, 2001.

[15] “International Commission in Radiation Units and Measurements: Determination of absorbed dose in a patient irradiated by beams of X or gamma rays in radiotherapy procedures ICRU Report No. 24,” (ICRU Publications, Washington, DC ), 1976.

[16] P. E. Lindsay *et al.*, “Multi-institutional Dosimetric and geometric commissioning of image-guided small animal irradiators,” *Med. Phys.*, vol. 41, no. 3, pp. 1–12, 2014.

[17] J. Newton *et al.*, “Commissioning a small-field biological irradiator using point, 2D, and 3D dosimetry techniques,” *Med. Phys.*, vol. 38, no. 12, pp. 6754–6762, 2011.

[18] E. Tryggstad, M. Armour, I. Iordachita, F. Verhaegen, and J. W. Wong, “A comprehensive system for dosimetric commissioning and Monte Carlo validation for the small animal radiation research platform,” *Phys. Med. Biol.*, vol. 54, no. 17, pp. 5341–5357, 2009.

[19] T. V. Feddersen, P. Rowshanfarzad, T. N. Abel, and M. A. Ebert, “Commissioning and performance characteristics of a pre-clinical image-guided radiotherapy system,” *Australas. Phys. Eng. Sci. Med.*, vol. 42, no. 2, pp. 541–551, 2019.

[20] S. Stojadinovic *et al.*, “MicroRT - Small animal conformal irradiator,” *Med. Phys.*, vol. 34, no. 12, pp. 4706–4716, 2007.

[21] R. Pidikiti *et al.*, “Dosimetric characterization of an image-guided stereotactic small animal irradiator,” *Phys. Med. Biol.*, vol. 56, no. 8, pp. 2585–2599, 2011.

[22] H. Zhou *et al.*, “NIH Public Access,” vol. 78, no. 1, pp. 297–305, 2011.

[23] R. Clarkson *et al.*, “Characterization of image quality and image-guidance performance of a preclinical microirradiator,” *Med. Phys.*, vol. 38, no. 2, pp. 845–856, 2011.

[24] Y. F. Wang, S. C. Lin, Y. H. Na, P. J. Black, and C. S. Wu, “Dosimetric verification and commissioning for a small animal image-guided irradiator,” *Phys. Med. Biol.*, vol. 63, no. 14, 2018.

[25] I. Silvestre Patallo *et al.*, “Development and Implementation of an End-To-End Test for Absolute Dose Verification of Small Animal Preclinical Irradiation Research Platforms,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 107, no. 3, pp. 587–596, 2020.

[26] P. Haraldsson, S. Å. J. Bäck, P. Magnusson, and L. E. Olsson, “Dose response characteristics and basic dose distribution data for a polymerization-based dosimeter gel evaluated using MR,” *Br. J. Radiol.*, vol. 73, no. 865, pp. 58–65, 2000.

- 562 [27] H. L. Andrews, R. E. Murphy, and E. J. LeBrun, "Gel dosimeter for depth-dose measurements," *Rev. Sci. Instrum.*, vol.  
563 28, no. 5, pp. 329–332, 1957.
- 564 [28] C. Baldock, Y. De Deene, M. Oldham, M. Mcjury, E. Pappas, and T. Maris, "Physics in Medicine & Biology Related  
565 content Magnetic resonance imaging of radiation dose distributions using a polymer-gel dosimeter Magnetic resonance  
566 imaging of radiation dose distributions using a polymer-gel dosimeter," 1994.
- 567 [29] G. S. Ibbott, "Clinical applications of gel dosimeters," *J. Phys. Conf. Ser.*, vol. 56, no. 1, pp. 108–131, 2006.
- 568 [30] M. Oldham, J. H. Siewerdsen, A. Shetty, and D. A. Jaffray, "High resolution gel-dosimetry by optical-CT and MR  
569 scanning," *Med. Phys.*, vol. 28, no. 7, pp. 1436–1445, 2001.
- 570 [31] K. Aljarrah, G. C. Sharp, T. Neicu, and S. B. Jiang, "Determination of the initial beam parameters in Monte Carlo linac  
571 simulation," *Med. Phys.*, vol. 33, no. 4, pp. 850–858, 2006.
- 572 [32] C. Baldock *et al.*, "Polymer gel dosimetry," *Phys. Med. Biol.*, vol. 55, no. 5, 2010.
- 573 [33] L. J. Schreiner, "True 3D chemical dosimetry (gels, plastics): Development and clinical role," *J. Phys. Conf. Ser.*, vol.  
574 573, no. 1, 2015.
- 575 [34] M. Oldham, "Radiochromic 3D Detectors," *J. Phys. Conf. Ser.*, vol. 573, no. 1, 2015.
- 576 [35] J. C. Gore and Y. S. Kang, "Measurement of radiation dose distributions by nuclear magnetic resonance (NMR)  
577 imaging," *Phys. Med. Biol.*, vol. 29, no. 10, pp. 1189–1197, 1984.
- 578 [36] M. J. Maryański, Y. Z. Zastavker, and J. C. Gore, "Radiation dose distributions in three dimensions from tomographic  
579 optical density scanning of polymer gels: II. Optical properties of the BANG polymer gel," *Phys. Med. Biol.*, vol. 41, no.  
580 12, pp. 2705–2717, 1996.
- 581 [37] R. G. Kelly, K. J. Jordan, and J. J. Battista, "Optical CT reconstruction of 3D dose distributions using the ferrous-  
582 benzoic-xyleneol (FBX) gel dosimeter," *Med. Phys.*, vol. 25, no. 9, pp. 1741–1750, 1998.
- 583 [38] A. Jirasek, "Considerations for x-ray CT polymer gel dosimetry," *J. Phys. Conf. Ser.*, vol. 444, no. 1, 2013.
- 584 [39] G. J. Salomons, Y. S. Park, and B. Kim, "Physics in Medicine & Biology Related content Polymer gel dosimetry using x-  
585 ray computed tomography : a feasibility study 4 Polymer gel dosimetry using x-ray computed tomography : a feasibility  
586 study \*," 2000.
- 587 [40] J. Vandecasteele and Y. De Deene, "Evaluation of radiochromic gel dosimetry and polymer gel dosimetry in a clinical  
588 dose verification," *Phys. Med. Biol.*, vol. 58, no. 18, pp. 6241–6262, 2013.
- 589 [41] Y. Watanabe, L. Warmington, and N. Gopishankar, "Three-dimensional radiation dosimetry using polymer gel and solid  
590 radiochromic polymer: From basics to clinical applications," *World J. Radiol.*, vol. 9, no. 3, p. 112, 2017.
- 591 [42] C. Bayreder, D. Georg, E. Moser, and A. Berg, "Basic investigations on the performance of a normoxic polymer gel with

- 592 tetrakis-hydroxy-methyl-phosphonium chloride as an oxygen scavenger: Reproducibility, accuracy, stability, and dose  
593 rate dependence,” *Med. Phys.*, vol. 33, no. 7, pp. 2506–2518, 2006.
- 594 [43] Y. De Deene, K. Vergote, C. Claeys, and C. De Wagter, “The fundamental radiation properties of normoxic polymer gel  
595 dosimeters: A comparison between a methacrylic acid based gel and acrylamide based gels,” *Phys. Med. Biol.*, vol. 51,  
596 no. 3, pp. 653–673, 2006.
- 597 [44] A. Karlsson, H. Gustavsson, S. Månsson, K. B. McAuley, and S. Å. J. Bäck, “Dose integration characteristics in  
598 normoxic polymer gel dosimetry investigated using sequential beam irradiation,” *Phys. Med. Biol.*, vol. 52, no. 15, pp.  
599 4697–4706, 2007.
- 600 [45] C. Baldock *et al.*, “Polymer gel dosimetry,” *Phys. Med. Biol.*, vol. 55, no. 5, pp. 1–87, 2010.
- 601 [46] P. Y. Guo, J. A. Adamovics, and M. Oldham, “Characterization of a new radiochromic three-dimensional dosimeter,”  
602 *Med. Phys.*, vol. 33, no. 5, pp. 1338–1345, 2006.
- 603 [47] “Clear View 3D Dosimeter.” [Online]. Available: <https://modusqa.com/dosimetry/dosimeters/clearview>. [Accessed: 21-  
604 Jan-2020].
- 605 [48] C. Huet, J. Colnot, and I. Clairand, “Preliminary investigation of the dosimetric properties of ClearView™ dosimeter,” in  
606 *Journal of Physics: Conference Series 2017;847:012015*, 2017.
- 607 [49] J. Colnot, C. Huet, R. Gschwind, and I. Clairand, “Characterisation of two new radiochromic gel dosimeters TruView™  
608 and ClearView™ in combination with the vista™ optical CT scanner: A feasibility study,” *Phys. Medica*, vol. 52, no.  
609 April, pp. 154–164, 2018.
- 610 [50] Ashland Inc., “GAFChromic™ EBT3 film specifications,” 2014. [Online]. Available:  
611 [http://www.gafchromic.com/documents/EBT3\\_Specifications.pdf](http://www.gafchromic.com/documents/EBT3_Specifications.pdf). [Accessed: 21-Jan-2020].
- 612 [51] V. M. Systems, “Linatron-M9 & M9A Modular high-energy X-ray source,” pp. 7–10.
- 613 [52] “EXRADIN ion chambers:Thimble ionization chambers,” 2010. [Online]. Available:  
614 [http://www.teambest.com/CNMC\\_docs/radPhysics/thimble/CNMC\\_PTW\\_pinpoint.pdf](http://www.teambest.com/CNMC_docs/radPhysics/thimble/CNMC_PTW_pinpoint.pdf). [Accessed: 21-Jan-2020].
- 615 [53] and D. W. O. R. Walters, B. R. B. Í., Iwan Kawrakow, “DOSXYZnrc Users Manual. Nrc Report Pirs,” 2005.
- 616 [54] and I. K. Rogers, D. W. O., B. Walters, “BEAMnrc Users Manual. Nrc Report Pirs,” 2009.
- 617 [55] C. Clift, A. Thomas, J. Adamovics, Z. Chang, I. Das, and M. Oldham, “Toward acquiring comprehensive radiosurgery  
618 field commissioning data using the PRESAGE®/ optical-CT 3D dosimetry system,” *Phys. Med. Biol.*, vol. 55, no. 5, pp.  
619 1279–1293, 2010.
- 620 [56] A. Fareed *et al.*, “Impact of iterative reconstruction vs. filtered back projection on image quality in 320-slice CT coronary  
621 angiography,” *Med. (United States)*, vol. 96, no. 48, pp. 1–5, 2017.

- 622 [57] T. Olding and L. J. Schreiner, "Cone-beam optical computed tomography for gel dosimetry II: Imaging protocols," *Phys.*  
623 *Med. Biol.*, vol. 56, no. 5, pp. 1259–1279, 2011.
- 624 [58] A. Niroomand-Rad *et al.*, "Radiochromic film dosimetry: Recommendations of AAPM Radiation Therapy Committee  
625 Task Group 55," *Med. Phys.*, vol. 25, no. 11, pp. 2093–2115, 1998.
- 626 [59] Ashland Inc., "User Manual FilmQA™ Pro," 2013.
- 627 [60] R. Nath *et al.*, "AAPM code of practice for radiotherapy accelerators: Report of AAPM Radiation Therapy Task Group  
628 No. 45," *Med. Phys.*, vol. 7, no. 21, pp. 1093–1121, 1994.
- 629 [61] M. J. Butson, T. Cheung, and P. K. N. Yu, "Absorption spectra variations of EBT radiochromic film from radiation  
630 exposure," *Phys. Med. Biol.*, vol. 50, no. 13, 2005.
- 631 [62] J. P. Gibbons *et al.*, "Monitor unit calculations for external photon and electron beams: Report of the AAPM Therapy  
632 Physics Committee Task Group No. 71," *Med. Phys.*, vol. 41, no. 3, 2014.
- 633 [63] W. Zhang, I. Oraiqat, H. Lei, P. L. Carson, I. E. I. Naqa, and X. Wang, "Dual-Modality X-Ray-Induced Radiation  
634 Acoustic and Ultrasound Imaging for Real-Time Monitoring of Radiotherapy," *BME Front.*, vol. 2020, 2020.

635

636

637 **Table of Figures:**

638

639 **Fig. 1.** Relative and absolute dosimetry measurement setup at 220 cm SSD and effective measurement depth of 2 cm in phantom  
640 (2 cm buildup thickness of solid water (a,c) or gel (b) ) (a) measurements setup using A14 ionization chamber (b) radiochromic  
641 gel jar (c) film measurement. Fig. 1 b) shows the integrated positioning lasers used to increase collimator and phantom  
642 positioning reproducibility and reduce production errors.

643 **Fig. 2.** (a) Clearview gel calibration curve relating optical density to dose in Gy and (b) the three color (red, blue, green)  
644 components of the film calibration curve relating the percent color response of the film to dose in Gy.

645 **Fig. 3.** Example rabbit irradiation setup showing the utilization of commissioned Linatron in small animal irradiation studies. (a)  
646 An euthanized rabbit was supported vertically with build-in holder and exposed to a 2x2 cm<sup>2</sup> field at 220 cm SSD( b). The total  
647 maximum dose was maintained to be < 20Gy per fraction as per the institutional animal protocol [63].

648 **Fig. 4.** Linatron output-timer linearity absolute measurement verification with A14 IC; absolute total dose measured as the  
649 average of three different trials and the error is the standard deviation between trials. The smaller error bars (much smaller than  
650 the marker sizes) represent the uncertainty in the measurements.

651 **Fig. 5.** 3D view of gel dose measurements (in optical density OD) per pixel position for the 1x1 cm<sup>2</sup> field showing the transverse  
652 and sagittal views of dose distributions in b, c for extracting beam profiles at 2 cm depth, and PDD curves respectively.

653 **Fig. 6.** Beam profiles of the  $0.5 \times 0.5 \text{ cm}^2$ ,  $1 \times 1 \text{ cm}^2$  and  $2 \times 2 \text{ cm}^2$  fields measured with gel dosimeter and EBT3 films at 2 cm  
654 reference depth in phantom; (a) the horizontal (in plane) beam profiles, (b) is the vertical (cross plane) beam profiles. Due to  
655 limited sensitivity of the gels for low doses, gel profiles were limited to absolute doses above 8 Gy.

656 **Fig. 7.** PDD curves, an average of three different trials, for each of the small radiation fields (a) Film based PDDs for all fields (b)  
657  $0.5 \times 0.5 \text{ cm}^2$ , (c)  $1 \times 1 \text{ cm}^2$ , (d)  $2 \times 2 \text{ cm}^2$  measured with gels and films. Error bars are represented for both film and gel as the point  
658 standard deviation between the three different trials.

659 **Fig. 8.** Beam profiles of primary collimated Linatron beam divergence (5.08 cm diameter) with distance from the beam exit  
660 measured with films at beam exit, 1.25 m and at 2.5 m from beam exit.

661 **Fig. 9.** Inverse-square law fitting verification of dose (in Gy) measured with films as a function of distance from source (in  
662 meters).

663 **Fig. 10.** Isodose contour plots of the different small field profiles at a depth of 2 cm for gels and films. Isodose lines are 90, 80,  
664 60, and 40%. a)  $0.5 \times 0.5 \text{ cm}^2$  field, b)  $1 \times 1 \text{ cm}^2$  field and c)  $2 \times 2 \text{ cm}^2$  field.

665 **Fig. 11.** Isodose contour plots (90, 80, 70, 60, 50 and 40%) for the different small field plane PDDs for gels and films normalized  
666 to the maximum dose. A)  $0.5 \times 0.5 \text{ cm}^2$  field, b)  $1 \times 1 \text{ cm}^2$  field and c)  $2 \times 2 \text{ cm}^2$  field.

667

Author Manuscript

**Table 1.** Daily Linatron output variability with time (intra-day variability) for 3 minutes of irradiation

Irradiation Time (Hours)	5/3/2019		5/4/2019	
	Absolute Dose (cGy/min)	Linatron Output Reading( cGy/min)	Absolute Dose (cGy/min)	Linatron Output Reading( cGy/min)
0.00	146.41±0.49	601.23±0.81	146.64±0.85	603.5±0.95
2.50	147.97±0.28	600.67±1.28	148.05±0.38	601.47±0.36
3.50	148.52±0.47	601.40±0.69	--	--

**Table 2.** First operation Linatron output variability with date of exposure (inter-day variability)

Date of irradiation	Absolute Dose (cGy/min)	Linatron Output Reading (cGy/min)
5/3/2019	146.41±0.49	601.22±0.81
21/3/2019	144.58±0.32	595.42±0.86
5/4/2019	146.64±0.85	603.5±0.95
11/4/2019	145.57±0.11	597.76±11.84

**Table 3.** Beam profile characteristics at 2 cm depth in phantom using films and gels

	Field Width (cm)		Left Penumbra (cm)		Right Penumbra (cm)	
	Film	Gel	Film	Gel	Film	Gel
0.5x0.5 cm <sup>2</sup>	0.48±0.04	0.50±0.01	0.15±0.02	0.19±0.11	0.15±0.01	0.20±0.09

<b>1x1 cm<sup>2</sup></b>	0.96±0.03	0.99±0.05	0.20±0.02	0.23±0.07	0.20±0.07	0.22±0.01*
<b>2x2 cm<sup>2</sup></b>	1.98±0.01*	2.06±0.01*	0.26±0.01	0.35±0.02	0.34±0.01*	0.24±0.01


\* A minimum error value in measurement of 0.01 cm is reported here for the beam profiles extracted from film. Similarly, for the error value in the right penumbra measured with both gel and films.

**Table 4.** ROFs of the different Linatron field sizes relative to the 2x2 cm<sup>2</sup> field

<b>Field Size (cm<sup>2</sup>)</b>	<b>Film ROF</b>	<b>Gel ROF</b>	<b>Relative % Difference</b>
0.5x0.5	0.70±0.03	0.67±0.01	4.3 %
1x1	0.89±0.03	0.88±0.02	1.1 %
2x2	1.00±0.05	1.00±0.01	0.00%

**Table 5.** The field size diversion data with distance from the target source

<b>SSD (cm)</b>	<b>Measured Field (cm)</b>	<b>Calculated Field(cm)</b>	<b>Relative % Error</b>
<b>161</b>	5.75	5.49	4.53
<b>286</b>	9.81	9.63	1.83
<b>411</b>	14.00	13.84	1.14



mp\_14685\_f1a.jpg






mp\_14685\_f1b.jpg


Autho



mp\_14685\_f1c.jpg



mp\_14685\_f2a.jpg




mp\_14685\_f2b.jpg




mp\_14685\_f3a.jpg

Autho




mp\_14685\_f3b.jpg




mp\_14685\_f4.jpg

# Author Manuscript




mp\_14685\_f5a.jpg







mp\_14685\_f5b.jpg




mp\_14685\_f5c.jpg




mp\_14685\_f6a.jpg




mp\_14685\_f6b.jpg




mp\_14685\_f7a.jpg



mp\_14685\_f7b.jpg




mp\_14685\_f7c.jpg




mp\_14685\_f7d.jpg




# Author Manuscript




mp\_14685\_f8.jpg




mp\_14685\_f9.jpg




mp\_14685\_f10a.jpg




mp\_14685\_f10b.jpg




mp\_14685\_f10c.jpg



mp\_14685\_f11a.jpg



mp\_14685\_f11b.jpg



mp\_14685\_f11c.jpg